This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A second look at Idorsia's phase III trials results for its resistant hypertension drug, Aprocitentan
Ticker(s): IDRSF, CINC, AZN, KBP BiosciencesWho's the expert?
Institution: NYU
Bio:
- Director of Division of Nephrology, Norman S. Wikler Professor of Medicine & Professor of Pharmacology at NYU Langone.
- In practice for 33 years, double board certified in Nephrology and Internal Medicine, and has extensive experience treating patients with CKD and FSGS.
- Manages roughly 8 patients with C3G and is very familiar with the BCX9930 data on C3G
- Published a number of articles in peer reviewed journals and member of several professional organizations including The American Society for Clinical Investigation
Interview GoalDiscussing the current treatment landscape for resistant hypertension and PRECISION, the Phase 3 study investigating Aprocitentan, a dual endothelin receptor antagonist.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
